# Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin

> **NCT00630877** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 276 (actual)

## Conditions studied

- Dyslipidemia

## Interventions

- **DRUG:** Niacin extended-release (NER)
- **DRUG:** Niacin extended-release (NER) placebo
- **DRUG:** Aspirin (ASA)
- **DRUG:** Aspirin (ASA) placebo

## Key facts

- **NCT ID:** NCT00630877
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 276 (ACTUAL)
- **Last updated:** 2009-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00630877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00630877, "Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00630877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*